(Reuters) - The biotechnology company said the outcome of the re-examination, which was requested by Neuralstem, would have no material impact on its patent porfolio.
StemCells said petitioning for patent re-examination and a stay is a procedural tactic often used by defendants to delay a trial.
Read more at Reuters.com Government Filings News
StemCells said petitioning for patent re-examination and a stay is a procedural tactic often used by defendants to delay a trial.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment